Goldman Sachs Group Inc Brooklyn Immuno Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.23 - $0.71 $3,848 - $11,880	-16,733 Reduced 17.77%	77,405 $19,000
Q3 2022 Nov 10, 2022	SELL	$0.23 - $0.71 $3,848 - $11,880	-16,733 Reduced 17.77%	77,405 $0
Q2 2022 May 14, 2024	BUY	$0.48 - $2.03 $45,186 - $191,100	94,138 New	94,138 $48,000
Q2 2022 Aug 15, 2022	BUY	$0.48 - $2.03 $26,674 - $112,809	55,571 Added 144.09%	94,138 $48,000
Q1 2022 May 16, 2022	SELL	$1.76 - $4.84 $55,904 - $153,737	-31,764 Reduced 45.16%	38,567 $79,000
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $211,519 - $496,587	50,724 Added 258.7%	70,331 $293,000
Q3 2021 Nov 10, 2021	BUY	$8.86 - $17.05 $173,718 - $334,299	19,607 New	19,607 $182,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.